Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Hammond J, et al. Among authors: pypstra r. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H, File TM Jr, Mandell L, Ball P, Pypstra R, Thomas M; 185 Gemifloxacin Study Group. Lode H, et al. Among authors: pypstra r. Clin Ther. 2002 Nov;24(11):1915-36. doi: 10.1016/s0149-2918(02)80088-1. Clin Ther. 2002. PMID: 12501883 Clinical Trial.
Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis.
Wilson R, Langan C, Ball P, Bateman K, Pypstra R; Gemifloxacin 207 Clinical Study Group. Wilson R, et al. Among authors: pypstra r. Respir Med. 2003 Mar;97(3):242-9. doi: 10.1053/rmed.2003.1435. Respir Med. 2003. PMID: 12645831 Free article. Clinical Trial.
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Ansari W, Harrington MA, Simón-Campos A, Chew KW, Pypstra R, Rusnak JM. Hammond J, et al. Among authors: pypstra r. Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093/cid/ciae551. Online ahead of print. Clin Infect Dis. 2024. PMID: 39523543
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, Daikos GL, Wang M, Torre-Cisneros J, Singer G, Titov I, Gumenchuk I, Zhao Y, Jiménez-Rodríguez RM, Liang L, Chen G, Pyptiuk O, Aksoy F, Rogers H, Wible M, Arhin FF, Luckey A, Leaney JL, Pypstra R, Chow JW; COMBACTE-CARE consortium REVISIT study group. Carmeli Y, et al. Among authors: pypstra r. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00499-7. doi: 10.1016/S1473-3099(24)00499-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39389071
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM. Hammond J, et al. Among authors: pypstra r. N Engl J Med. 2024 Jul 18;391(3):224-234. doi: 10.1056/NEJMoa2309002. N Engl J Med. 2024. PMID: 39018532 Free PMC article. Clinical Trial.
11 results